Last edition
News about "wet Age-related Macular Degeneration "
Lupin Receives US FDA Approval for Interchangeable Biosimilar Ranibizumab, Ranluspec
Lupin has secured US FDA approval for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar to Lucentis, expanding its biosimilars portfolio and broadening access to treatments for retinal and vision-related disorders.
Wet Age-Related Macular Degeneration | 05/06/2026 | By News Bureau | 112
European Commission approves EYLUXVI (ALT-L9) by Alteogen
EYLUXVI is the second biosimilar approved by the European Commission for Alteogen, following the launch of the Herceptin biosimilar in China through its partner Qilu Pharmaceutical.
Wet Age-related Macular Degeneration | 18/09/2025 | By Dineshwori | 171
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy